| Literature DB >> 32660458 |
Atefeh Talebi1, Afsaneh Mohammadnejad2, Abolfazl Akbari1, Mohamad Amin Pourhoseingholi3, Hassan Doosti4, Bijan Moghimi-Dehkordi5, Shahram Agah6, Mansour Bahardoust7,8.
Abstract
BACKGROUND: Gastric cancer (GC) has been considered as the 5th most common type of cancer and the third leading cause of cancer-associated death worldwide. The aim of this historical cohort study was to evaluate the survival predictors for all patients with GC using the Cox proportional hazards, extended Cox, and gamma-frailty models.Entities:
Keywords: Akaike information criterion; Extended cox; Frailty; Gastric cancer; Survival analysis
Mesh:
Year: 2020 PMID: 32660458 PMCID: PMC7359591 DOI: 10.1186/s12893-020-00816-6
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Demographic and pathological characteristics of GC patients
| Demographic Characteristics | Censored | Dead | Total |
|---|---|---|---|
| Number Percent | Number Percent | Number Percent | |
| < 60 | 397 49.4 | 390 43.8 | 787 46.4 |
| > 60 | 403 50.1 | 501 56.2 | 904 53.3 |
| Male | 471 58.6 | 478 53.6 | 949 56 |
| Female | 333 41.4 | 413 46.4 | 746 44 |
| Unmarried | 50 6.2 | 51 5.7 | 101 6 |
| Married | 749 93.2 | 835 93.7 | 1584 93.5 |
| Illiterate | 220 27.4 | 125 14 | 345 20.4 |
| Primary | 199 24.8 | 199 22.3 | 398 23.5 |
| University | 58 7.2 | 88 9.9 | 146 8.6 |
| Yes | 201 25 | 263 29.5 | 464 27.4 |
| No | 563 70 | 576 64.6 | 1139 67.2 |
| < 18.5 | 92 11.4 | 112 12.6 | 204 12 |
| 18.6–24.9 | 394 49 | 453 50.8 | 847 50 |
| > 25 | 115 14.3 | 109 12.2 | 189 11.2 |
| Yes | 326 40.5 | 431 48.4 | 757 44.7 |
| No | 439 54.6 | 392 44 | 831 49 |
| Adenocarcinoma | 384 47.8 | 427 47.9 | 811 47.8 |
| Lymphoma | 73 9.1 | 44 4.9 | 117 6.9 |
| Other | 93 11.6 | 59 6.6 | 152 9 |
| N1 | 139 17.3 | 136 15.3 | 275 16.2 |
| N2 | 209 26 | 233 26.2 | 442 26.1 |
| N3 | 39 6.1 | 37 4.2 | 86 5.1 |
| Yes | 168 20.9 | 401 45 | 569 33.6 |
| No | 451 56.1 | 403 45.2 | 854 50.4 |
| Surgery | 437 54.3 | 470 52.7 | 907 53.5 |
| Surgery+ chemotherapy | 245 30.5 | 230 25.8 | 475 28 |
| Chemotherapy+ radiotherapy | 122 15.2 | 191 21.5 | 313 18.5 |
| T1 | 118 14.7 | 107 12 | 225 13.3 |
| T2 | 229 28.5 | 208 23.3 | 437 25.8 |
| T3 | 94 11.7 | 156 17.5 | 250 14.7 |
| Well | 286 35.6 | 300 33.7 | 586 34.6 |
| Moderate | 194 24.1 | 311 34.9 | 505 29.8 |
| Poorly | 124 15.4 | 110 12.3 | 234 13.8 |
| Undifferentiated | 165 20.5 | 126 14.1 | 291 17.2 |
Fig. 1Kaplan–Meier curve, 5-year survival rate
Univariate and multivariate analyses of CPH model for prognosis in GC patients
| Univariate | Multivariate | |
|---|---|---|
| HR P | HR P | |
| < 60 | Ref - | |
| > 60 | 1.006 0.03 | 1.01 0.018 |
| Male | Ref* - | |
| Female | 1.22 0.004 | |
| Unmarried | Ref - | |
| Married | 1.03 0.84 | |
| Illiterate | Ref - | |
| Less than diploma | 0.94 0.6 | |
| University | 0.82 0.17 | |
| Yes | Ref - | |
| No | 1.09 0.23 | |
| < 18 | 1.66 < 0.001 | 2.45 < 0.001 |
| 18–25 | 0.98 0.87 | 1.08 0.65 |
| > 25 | Ref | |
| No | Ref - | |
| Yes | 1.22 0.004 | |
| Other | Ref - | |
| Adenocarcinoma | 0.8 0.11 | |
| Lymphoma | 0.6 0.01 | |
| N1 | Ref - | |
| N2 | 1.4 0.002 | |
| N3 | 1.27 0.19 | |
| No | Ref - | |
| Yes | 1.3 < 0.001 | |
| Chemotherapy+ radiotherapy | Ref - | |
| Surgery+ chemotherapy | 0.58 0.001 | 0.79 0.011 |
| Surgery | 0.95 0.58 | 0.85 0.052 |
| T1 | Ref - | |
| T2 | 1.5 < 0.001 | 2.43 0.002 |
| T3 | 3.6 < 0.001 | 2.77 0.001 |
| Undifferentiated | Ref - | |
| Well | 0.73 0.004 | 0.650192 |
| Moderate | 0.83 0.088 | 0.38 < 0.001 |
| Poorly | 0.96 0.77 | 0.68 0.129 |
Abbreviations: HR: Hazard Ratio, Ref Reference group
PH assumption for the extended Cox and frailty models
| PH assumption | Frailty | |
|---|---|---|
| HR P | P (rho) HR P | |
| < 60 | Ref - | |
| > 60 | 1.25 0.08 | 0.0156 1.32 0.03 |
| Male | Ref - | |
| Female | 0.91 0.48 | 0.89 0.38 |
| Unmarried | Ref - | |
| Married | 1.88 0.041 | 1.74 0.07 |
| Illiterate | Ref - | |
| Less than diploma | 0.92 0.58 | 0.97 0.88 |
| University | 0.91 0.6 | 0.91 0.59 |
| Yes | Ref - | |
| No | 0.84 0.17 | 0.87 0.3 |
| < 18 | 2.7 < 0.001 | 0.0164 2.6 0.001 |
| 18–25 | 1.17 0.54 | 1.04 0.81 |
| > 25 | Ref - | |
| No | Ref - | |
| Yes | 1.08 0.52 | 1.11 0.41 |
| Other | Ref - | |
| Adenocarcinoma | 0.97 0.91 | 0.94 0.81 |
| Lymphoma | 0.89 0.72 | 0.81 0.49 |
| N1 | Ref - | |
| N2 | 1.25 0.08 | 1.21 0.14 |
| N3 | 0.83 0.43 | 0.83 0.43 |
| No | Ref - | |
| Yes | 0.95 0.71 | 0.98 0.86 |
| < 0.001 | ||
| Chemotherapy+ radiotherapy | Ref - | |
| Surgery+ chemotherapy | 0.69 0.001 | 0.81 0.021 |
| Surgery | 0.91 0.05 | 0.9 0.056 |
| T1 | Ref - | |
| T2 | 2.37 0.01 | 0.0158 2.27 0.013 |
| T3 | 3.04 0.002 | 2.53 0.008 |
| Undifferentiated | Ref - | |
| Well | 0.51 0.12 | 0.43 0.047 |
| Moderate | 0.30 0.002 | 0.26 0.001 |
| Poorly | 0.56 0.125 | 0.54 0.099 |
| Variance of Frailty 1.67 0.04 | ||